疫苗学《Vaccines》——6th Edition by (美)普洛特金

rojjer

Vaccines, 6th Edition

7 M  L  k- Q: `  \  Z/ s& VApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.
4 R- N+ Q8 {9 y/ o1 f
( }* X7 p( m3 k) Y) z( C- Ghttp://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606
. x) p8 G4 c) n, R* |+ R7 E
$ h2 P; c4 X! P* j: w+ M# YSECTION 1: General aspects of vaccination
1 A short history of vaccination 1
2 Vaccine immunology 14
- X5 E5 ~; ]/ ^" U. {- `3 The vaccine industry 33
% U$ T' |1 t) i# k( f4 Vaccine manufacturing 44
/ l  e( \: J% j; f& ~- E5 Evolution of adjuvants across the centuries 58
6 Vaccine additives and manufacturing residuals in the United States:
( e" T- J& p$ K# v7 r: ]+ zlicensed vaccines 71
! i3 q4 f' U* ]/ U) ]0 N7 Passive immunization 80
' }+ t. ?6 G9 _1 Y% t3 Q" {2 i8 General immunization practices 88
SECTION 2: Licensed vaccines
( q, M! D+ _0 U  T7 P+ i/ L9 Adenovirus vaccines 113
10 Anthrax vaccines 127
9 V) d/ K$ k4 g) \. f) e11 Cholera vaccines 141
12 Diphtheria toxoid 153
13 Haemophilus influenzae vaccines 167
14 Hepatitis A vaccines 183
15 Hepatitis B vaccines 205
16 Human papillomavirus vaccines 235
17 Inactivated influenza vaccines 257
18 Influenza vaccine-live 294
) ?6 f$ B. T# D0 m5 p8 \, L19 Japanese encephalitis vaccines 312
4 V* d0 a' @% N4 Y7 M20 Measles vaccines 352
8 ]8 @9 }- F& Y6 I% P4 a/ _% _21 Meningococcal vaccines 388
22 Mumps vaccine 419
+ k$ r; K7 ^1 ~* D23 Pertussis vaccines . 447
8 _+ t5 O) J# w8 O3 ?2 q3 o, r6 T24 Plague vaccines 493
5 i9 c, h% Q# I9 N# E25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
26 Pneumococcal polysaccharide vaccines 542
% U# k2 l" [4 @9 o9 U27 Poliovirus vaccine-inactivated . 573
/ w9 @$ B7 J8 ^8 h28 Poliovirus vaccine-live 598
/ S& u) P( M; ?) l9 F29 Rabies vaccines .646
  v  w  d) W/ s) C- j30 Rotavirus vaccines . 669
% j% o. q' D6 p$ x31 Rubella vaccine 688
32 Smallpox and vaccinia 718
5 P% y" B: L/ D33 Tetanus toxoid 746
0 r: E! R2 g  O+ u$ Y# L- g* _34 Tick-borne encephalitis virus vaccines 773
35 Tuberculosis vaccines 789
/ ~% X4 _0 W; t1 N36 Typhoid fever vaccines 812
37 Varicella vaccine 837
38 Yellow fever vaccine 870
39 Zoster vaccine 969
, u, z/ e% Y% w! w: N8 J; I40 Combination vaccines 981
% s9 [: F" ]4 a  a" VSECTION 3: Vaccines in development and new vaccine strategies
41 Biodefense and special pathogen vaccines 1008
42 Therapeutic cancer vaccines 1018
43 Cytomegalovirus vaccines 1032
44 Dengue vaccines 1042
, y, W$ {4 L" R; g' P. w4 d45 Diarrhea caused by bacteria 1052
46 Ebola vaccine 1060
47 Epstein-Barr virus vaccines 1068
48 Hepatitis C vaccines 1074
+ i7 S0 c; N/ H4 j( g% p49 Hepatitis E vaccines 1085
50 Herpes simplex virus vaccines 1090
2 ^8 X4 C) ]- x- p( J1 h% f51 Human immunodeficiency virus vaccines 1097
- q, d) j; |+ g; E8 T! o% m52 Lyme disease vaccines 1122
53 Malaria vaccines 1133
54 Noninfectious disease vaccines 1138
( j! Q; q0 H/ b8 r55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
% H  ?0 G6 d1 @  Q' K, ]& h$ B56 Parasitic disease vaccines 1154
57 Staphylococcus aureus vaccines 1161
58 Streptococcus group A vaccines 1169
( L. I7 ]) K' b- `( k6 f59 Streptococcus group B vaccines 1176
' ^5 m! i0 V) Q, C& A60 Technologies for making new vaccines 1182
1 M! ]& b3 U; l4 Q61 Alternative vaccine delivery methods 1200
9 k4 V. Q$ e0 E4 ]1 I; z62 The development of gene-based vectors for immunization 1232
* f( E! }( C, N. P+ z0 z0 fSECTION 4: Vaccination of special groups
63 Vaccination of immunocompromised hosts 1243
8 a! }3 g5 v: |  @6 U- ]64 Vaccination of human immunodeficiency virus-infected persons 1257
# p  k/ V8 V, v: f6 J% j7 h6 U0 I/ s' c65 Vaccines for international travel 1270
66 Vaccines for health care personnel 1290
1 Q' F. |/ A0 K% ]- w4 kSECTION 5: Public health and regulatory issues
67 Immunization in the United States 1310
68 Immunization in Europe . 1334
69 Immunization in the Asia-Pacific region 1353
2 V) a# i- Q9 _. U( h* B1 [4 q5 D70 Immunization in developing countries 1369
# l8 t; n9 i% G71 Community immunity 1395
2 u3 J9 z8 B( ~/ u9 C7 X72 Economic analyses of vaccine policies 1413
73 Regulation and testing of vaccines 1427
74 Regulation of vaccines in Europe 1447
" \" D( ^% C. k! E3 u9 ?! i# K75 Regulation of vaccines in developing countries 1454
76 Vaccine safety 1464
77 Legal issues . 1481
78 Ethics 1508

- ~: B( J( e# D7 Q

" x+ e- ?7 A' D, h9 H$ ]" D$ s! i2 w
! }$ x1 {' X( e; D

casarett

Vaccines, 6e, 2012

Hardcover: 1570 pages
Publisher: Saunders; 6 edition (October 30, 2012)
Language: English
ISBN-10: 1455700908
Size: 52.3mb (original pdf)

" H6 |- h5 |, ]$ d. K' o2013 BMA Medical Book Awards Highly Commended in Public Health!
Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice!
5 n* u6 D' F! F3 z" o) B5 c
Gain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
( s' ?+ f  Q% H5 g% Y5 oUpdate your knowledge of both existing vaccines and vaccines currently in the research and development stage.
Get complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
* z0 s, E5 m3 l) T# {% `0 WAnalyze the cost-benefit and cost-effectiveness of different vaccine options.
Clearly visualize concepts and objective data through an abundance of tables and figures.
Perform seamless searches of the complete text online, access all the references, and download all the images at www.expertconsult.com.
2 v0 S$ b& R4 k* uMake optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.
; [, Y# u% X/ r( z: qStay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.

Download link: http://pan.baidu.com/s/1i5NxwLR
7 b+ \" ?. _  ?Code for downloading: dv96

rojjer

2 v( K- n- c& D% h  @$ O' wVaccines, 6th Edition

3 F$ M5 i7 R+ x: @Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.
$ g: t; r" q1 @' M1 ]
http://yun.baidu.com/share/link? ... 1&uk=3810996606

SECTION 1: General aspects of vaccination
" h/ \; v0 e8 m- O% e# I9 X! l1 A short history of vaccination 1
  ^& x1 b# _& n" z& A) [2 Vaccine immunology 14
+ w& d2 K; P/ V* Y- B1 ^3 The vaccine industry 33
4 Vaccine manufacturing 44
5 Evolution of adjuvants across the centuries 58
1 H2 B, K" U5 Z% V/ ^' e! P6 Vaccine additives and manufacturing residuals in the United States:
$ p$ Y, b1 T' x, Z1 U- jlicensed vaccines 71
8 j- l, |5 S6 ~' x2 x7 Passive immunization 80
8 General immunization practices 88
/ x+ Z9 j7 S8 X. E% y3 bSECTION 2: Licensed vaccines
9 Adenovirus vaccines 113
10 Anthrax vaccines 127
11 Cholera vaccines 141
. u5 v  z5 g- s$ l12 Diphtheria toxoid 153
13 Haemophilus influenzae vaccines 167
14 Hepatitis A vaccines 183
15 Hepatitis B vaccines 205
16 Human papillomavirus vaccines 235
2 Q) _5 t% Y5 t8 c' I2 C17 Inactivated influenza vaccines 257
18 Influenza vaccine-live 294
19 Japanese encephalitis vaccines 312
; @% }; _. N% J" x& C5 p, B% J20 Measles vaccines 352
21 Meningococcal vaccines 388
9 W( O. {6 }% b+ H  G22 Mumps vaccine 419
+ w/ T) e& l2 @' d23 Pertussis vaccines . 447
24 Plague vaccines 493
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
+ r7 d  ~9 D: N6 i2 u: V! P6 s26 Pneumococcal polysaccharide vaccines 542
27 Poliovirus vaccine-inactivated . 573
28 Poliovirus vaccine-live 598
. _1 F+ k* T4 F/ d29 Rabies vaccines .646
30 Rotavirus vaccines . 669
3 I3 x$ a9 ~  P# D31 Rubella vaccine 688
32 Smallpox and vaccinia 718
: q# n# x7 U! M5 x, L33 Tetanus toxoid 746
! i6 a6 i5 q1 q# o5 q$ X34 Tick-borne encephalitis virus vaccines 773
35 Tuberculosis vaccines 789
36 Typhoid fever vaccines 812
0 O2 ?& r' b. I- |  ]37 Varicella vaccine 837
7 @4 ^# e/ l6 [5 |( w! J38 Yellow fever vaccine 870
8 l# B# F. K5 `39 Zoster vaccine 969
40 Combination vaccines 981
SECTION 3: Vaccines in development and new vaccine strategies
41 Biodefense and special pathogen vaccines 1008
42 Therapeutic cancer vaccines 1018
43 Cytomegalovirus vaccines 1032
44 Dengue vaccines 1042
45 Diarrhea caused by bacteria 1052
46 Ebola vaccine 1060
2 I1 m& q% J* O+ z47 Epstein-Barr virus vaccines 1068
48 Hepatitis C vaccines 1074
49 Hepatitis E vaccines 1085
50 Herpes simplex virus vaccines 1090
, R" o' y, V; V! c6 m- a51 Human immunodeficiency virus vaccines 1097
52 Lyme disease vaccines 1122
" ~- N1 \* j. I1 N5 {53 Malaria vaccines 1133
54 Noninfectious disease vaccines 1138
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
/ o5 ]( Y& t" J8 \& Z56 Parasitic disease vaccines 1154
$ J! A$ V8 N  h3 ]( R, Z57 Staphylococcus aureus vaccines 1161
58 Streptococcus group A vaccines 1169
59 Streptococcus group B vaccines 1176
* J* p+ I! j# U; S60 Technologies for making new vaccines 1182
61 Alternative vaccine delivery methods 1200
, j: R6 [+ V& h6 a' R! K7 S5 \" a62 The development of gene-based vectors for immunization 1232
& ?) O" R* s8 e' L/ p& fSECTION 4: Vaccination of special groups
# U% i: d; H, d  G" `63 Vaccination of immunocompromised hosts 1243
& O0 r" {- l3 _" V4 h- ^64 Vaccination of human immunodeficiency virus-infected persons 1257
, Y2 _" G  j4 |- ^2 a& t* s9 Q$ U65 Vaccines for international travel 1270
3 G# `+ y4 C4 {) |* B9 J4 V: W66 Vaccines for health care personnel 1290
SECTION 5: Public health and regulatory issues
( p, A0 O- [! D1 i7 I5 S67 Immunization in the United States 1310
# B# d9 C: \% c' s, Z; x68 Immunization in Europe . 1334
69 Immunization in the Asia-Pacific region 1353
70 Immunization in developing countries 1369
71 Community immunity 1395
72 Economic analyses of vaccine policies 1413
% U) _5 p; Y3 s1 j& J5 |73 Regulation and testing of vaccines 1427
74 Regulation of vaccines in Europe 1447
$ W/ m' {1 N% O* A: B9 ?) h75 Regulation of vaccines in developing countries 1454
76 Vaccine safety 1464
4 y6 g0 ^' d( Y" ?9 s77 Legal issues . 1481
/ q- v0 a$ w: f, L8 a; l9 w0 r- U78 Ethics 1508
! q. T! A+ o/ y4 y9 l. v1 u

% E: R( Y4 H2 K" [- z

zhpu2008

怎么看不到相关下载呀

zhpu2008

谢谢分享

salina

非常感谢